Kventiax (Quetiapine)

Quetiapine works by blocking several neurotransmitter receptors, notably serotonin 5‑HT2A and dopamine D2, as well as histamine H1 and adrenergic α1 receptors. This multi‑receptor antagonism balances neurotransmission, reducing psychotic symptoms, stabilizing mood, and enhancing antidepressant effects.

The appropriate dose of Kventiax is individualized by the prescribing clinician based on the specific diagnosis, severity of symptoms, patient age, renal and hepatic function, and response to therapy. No fixed regimen is provided here.

Safety data for quetiapine in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made in consultation with a healthcare professional.

To order Kventiax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kventiax (quetiapine) shares the broad receptor profile typical of atypical antipsychotics but is distinguished by its relatively lower propensity for extrapyramidal symptoms and its utility as an adjunct in depression. Compared with agents like risperidone or olanzapine, it may cause more sedation and weight gain, while offering flexible dosing for mood stabilization.

Kventiax should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct light to maintain its stability throughout its shelf life.

Kventiax is taken orally. The tablet should be swallowed whole with a glass of water and may be taken with or without food, as directed by the prescribing clinician.

The most serious adverse reactions include neuroleptic malignant syndrome, a rare but life‑threatening condition; tardive dyskinesia, which involves persistent involuntary movements; and agranulocytosis, a severe drop in white blood cells. Patients should be monitored closely for any signs of these events.

Kventiax is contraindicated in individuals with known hypersensitivity to quetiapine or any of its excipients. It should also be avoided in patients with uncontrolled narrow‑angle glaucoma or those taking medications that may cause dangerous interactions without appropriate monitoring.